We are live on ! Find out more
TCRT icon

Alaunos Therapeutics

138 hedge funds and large institutions have $570M invested in Alaunos Therapeutics in 2015 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 54 increasing their positions, 43 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 43

12% less funds holding

Funds holding: 156138 (-18)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

28% less capital invested

Capital invested by funds: $794M → $570M (-$225M)

38% less call options, than puts

Call options by funds: $19.2M | Put options by funds: $30.8M

50% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 36

Holders
138
Holders Change
-18
Holders Change %
-11.54%
% of All Funds
3.85%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.11%
New
18
Increased
54
Reduced
43
Closed
36
Calls
$19.2M
Puts
$30.8M
Net Calls
-$11.7M
Net Calls Change
+$10.1M
Name Holding Trade Value Shares
Change
Change in
Stake
RIA
176
Regal Investment Advisors
Michigan
-$1K -1 Closed
SIG
177
Stanford Investment Group
California
-$1K

TCRT Hedge Fund Activity: Q3 2015 in Review

138 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2015, worth a combined $570M — down 28% from $794M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of TCRT and 18 opened new positions — a net loss of 18 holders — while 43 trimmed existing stakes and 54 added.

The largest buyer was Susquehanna International Group, adding an estimated $7.26M. The largest seller was Third Point, exiting entirely with an estimated $23.4M sold.

  • 138 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2015, down from 156 in Q2 2015.
  • Funds reported $570M of Alaunos Therapeutics stock for Q3 2015, down 28% quarter-over-quarter.
  • 18 funds opened new Alaunos Therapeutics positions in Q3 2015 and 36 closed out, a net change of -18 holders.
  • The largest Alaunos Therapeutics buyer in Q3 2015 was Susquehanna International Group, an estimated $7.26M added.
  • The largest Alaunos Therapeutics seller in Q3 2015 was Third Point, an estimated $23.4M sold.

Based on aggregated 13F filings for Q3 2015.